Eric Carter, M.D., PH.D.
Former CMO of Allergan
Eric Carter, M.D., PH.D. is a pharmaceutical industry executive with more than 2 decades of global pharmaceutical and device research and development experience in multiple therapeutic areas with significant people, portfolio, business development and budget responsibilities. Dr. Carter has demonstrated leadership in large, mid and small pharma settings and has a proven record of success in the introduction of new candidates into clinical development, in the introduction of new therapies into clinical practice to address unmet medical needs and in value-adding activities in support of commercialized medicines.
Dr. Carter served as Senior Vice President, Chief Medical Officer, Global Head of Clinical and Non-clinical Development of Allergan, Inc from 2011 through its acquisition by Actavis Pharmaceuticals in 2015. At Allergan he was responsible for non-clinical development, global clinical development and operations, safety, pharmacovigilance and epidemiology and R&D QA in ophthalmology, dermatology, urology, CNS and plastic surgery for small molecule and biologics, drugs and devices. He led the organization through a period of global growth and transformation and played a key role in Allergan’s independent recognition as a highly successful global R&D organization.
Prior to Allergan, Dr. Carter served as Chief Science Officer, Head of R&D and Chief Medical Officer of King Pharmaceuticals from 2007 until the company was acquired by Pfizer in 2011. Prior to King, Dr. Carter worked for Glaxo Wellcome and GSK where he held positions of increasing responsibility in global clinical development and medical affairs. Dr. Carter started his career in industry at Pharmacia which he joined from academic medical practice at the University of North Carolina, Chapel Hill with board certifications in Internal Medicine, Gastroenterology and Hepatology and Clinical Nutrition. He received his M.D. from the University of Miami, FL and his PH.D. from the University of Cambridge, England.